Definition
Description
Top Gene Interactions
Related Pathways
General Information
- Metabolism: Hepatic Route of Elimination: The main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. Approximately 2% of fluvoxamine was excreted in urine unchanged. Following a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours. Half Life: 15.6 hours
- Uses/Sources: For management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.
- Symptoms: Side effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.
- Treatment: Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for fluvoxamine are known. (L1712)
- Route of Exposure: Oral. Well absorbed, bioavailability of fluvoxamine maleate is 53%.
Mechanism of Action
Target Name | Mechanism of Action | References |
---|---|---|
Potassium voltage-gated channel subfamily H member 2 Muscarinic acetylcholine receptor M1 Sodium-dependent dopamine transporter Sodium-dependent noradrenaline transporter Cytochrome P450 2C9 |
14761192 9400006 10691690 12232544 20071423 12620070 9537821 |
|
5-hydroxytryptamine receptor 2A 5-hydroxytryptamine receptor 1A Sodium-dependent serotonin transporter |
The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs. |
12208313 11243491 11817517 11068436 12480170 9400006 12444499 12232544 11862346 15170064 11304754 12721776 12695316 11281985 9537821 11166521 12886034 12422060 |
Fluvoxamine Interacts with Diseases
Disease | Inference Score | References/Inference Genes |
Autism | 11.88 |
|
Mycoplasma Infections | 8.9 |
|
Chronic obstructive pulmonary disease | 8.76 |
|
Status Epilepticus | 8.09 |
|
Diabetes Mellitus, Type 2 | 8.07 |
|
Hypertension, Essential | 7.62 |
|
Manganese Poisoning | 7.31 |
|
Torsades de pointes | 6.98 |
|
Endotoxemia | 6.89 |
|
Breast carcinoma | 6.82 |
|
Myocardial Reperfusion Injury | 6.71 |
|
Cardiomyopathy, Dilated, 1E | 6.32 |
|
Long Qt Syndrome 3 | 6.32 |
|
Long QT syndrome type 3 | 6.32 |
|
Sick Sinus Syndrome 1, Autosomal Recessive | 6.32 |
|
Reperfusion Injury | 6.1 |
|
Subarachnoid Hemorrhage | 6.04 |
|
Cerebral Palsy, Spastic Quadriplegic, 1 | 5.98 |
|
Paroxysmal ventricular fibrillation | 5.98 |
|
PROGRESSIVE FAMILIAL HEART BLOCK, TYPE IA | 5.98 |
|